Published in J Natl Cancer Inst on October 28, 2011
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med (1991) 6.33
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (2010) 4.95
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst (2006) 4.01
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer (2005) 2.25
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer (1993) 2.08
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
Cost of neutropenic complications of chemotherapy. Ann Oncol (2007) 1.50
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev (2008) 1.45
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood (1997) 1.13
Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer (2010) 1.03
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol (1995) 0.95
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol (1998) 0.94
Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer. J Clin Oncol (1995) 0.93
Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst (2011) 0.89
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma. Br J Cancer (2006) 0.81
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF. Ann Oncol (1994) 0.80
Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma. Br J Cancer (2008) 0.80
Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol (2000) 0.78
Are guidelines on use of colony-stimulating factors in solid cancers flawed? Intern Med J (2009) 0.77
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol (2004) 7.45
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 6.62
Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med (2009) 5.75
Aggressiveness of cancer care near the end of life: is it a quality-of-care issue? J Clin Oncol (2008) 5.61
Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet (2004) 4.99
Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol (2003) 4.50
Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A (2002) 4.37
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol (2003) 4.24
Associations between palliative chemotherapy and adult cancer patients' end of life care and place of death: prospective cohort study. BMJ (2014) 3.90
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2012) 3.72
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med (2010) 3.24
Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst (2012) 3.16
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
End-of-life discussions, goal attainment, and distress at the end of life: predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol (2010) 2.97
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol (2013) 2.91
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care (2005) 2.75
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst (2002) 2.71
American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol (2008) 2.69
Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol (2014) 2.62
Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA (2012) 2.56
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst (2008) 2.56
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Developing a system to assess the quality of cancer care: ASCO's national initiative on cancer care quality. J Clin Oncol (2004) 2.52
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol (2005) 2.52
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol (2005) 2.48
A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst (2011) 2.48
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich) (2008) 2.37
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst (2006) 2.34
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol (2006) 2.29
A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg (2006) 2.29
Identifying cancer relapse using SEER-Medicare data. Med Care (2002) 2.28
Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. Med Care (2013) 2.22
Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol (2012) 2.21
Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst (2009) 2.20
NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements (2010) 2.19
Patients' experiences with care for lung cancer and colorectal cancer: findings from the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2010) 2.16
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. J Cancer Surviv (2011) 2.15
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
Parents' views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol (2008) 2.12
Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers. J Natl Cancer Inst (2003) 2.11
End-of-life care discussions among patients with advanced cancer: a cohort study. Ann Intern Med (2012) 2.08
The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol (2009) 2.02
Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med (2013) 2.00
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Hospital episodes and physician visits: the concordance between self-reports and medicare claims. Med Care (2007) 1.96
Associations between end-of-life discussion characteristics and care received near death: a prospective cohort study. J Clin Oncol (2012) 1.95
Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.94
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Treatment decision making in early-stage breast cancer: should surgeons match patients' desired level of involvement? J Clin Oncol (2002) 1.89
Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica (2007) 1.87
Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol (2007) 1.87
A snapshot of smokers after lung and colorectal cancer diagnosis. Cancer (2012) 1.85
Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol (2010) 1.84
Are electronic health records ready for genomic medicine? Genet Med (2009) 1.82
Deterioration of blood pressure control after discontinuation of a physician-pharmacist collaborative intervention. Pharmacotherapy (2010) 1.82
Breast implant-associated anaplastic large cell lymphoma: a systematic review. Plast Reconstr Surg (2015) 1.80
Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care (2007) 1.80
Parent and physician perspectives on quality of care at the end of life in children with cancer. J Clin Oncol (2005) 1.78
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med (2009) 1.77
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer (2012) 1.75
Hope and prognostic disclosure. J Clin Oncol (2007) 1.73
Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa. Health Serv Res (2003) 1.72
Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Med Care (2005) 1.71
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst (2011) 1.71
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Asthma and farm exposures in a cohort of rural Iowa children. Environ Health Perspect (2005) 1.71
Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst (2005) 1.70
Selecting high priority quality measures for breast cancer quality improvement. Med Care (2008) 1.70
Medical oncologists' perceptions of financial incentives in cancer care. J Clin Oncol (2012) 1.69
Communication about prognosis between parents and physicians of children with cancer: parent preferences and the impact of prognostic information. J Clin Oncol (2006) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Physicians' decision-making style and psychosocial outcomes among cancer survivors. Patient Educ Couns (2009) 1.65